Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference
26 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
25 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO)...
Pharmaceutical Contract Manufacturing Market Projected to Reach $222 Billion by 2028, Driven by Growing Demand for Generic and Specialty Medicines
25 sept. 2023 09h33 HE
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Manufacturing Market: Trends, Opportunities and Competitive Analysis 2023-2028" report has been added to ...
Societal CDMO Announces Corporate Restructuring
20 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Global Pharmaceuticals and Biotechnology Manufacturing and Supply Deals Analysis Report and Directory 2023
18 sept. 2023 07h28 HE
|
Research and Markets
Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2023" report has been added to ResearchAndMarkets.com's...
Stem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: Visiongain
13 sept. 2023 09h09 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Stem Cell Therapy Contract Manufacturing Market Report 2023-2033: Forecasts by Scale of Operation (Commercial, Clinical, Preclinical), by Size of...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023
07 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
07 sept. 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
31 août 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock
29 août 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving...